Drug Trial Radar · NCT03830333
Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)
Last checked: Nov 20, 2026Latest source record: Jan 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
268
Actual
Start
Mar 20, 2019
Primary completion
Oct 14, 2020
Study completion Oct 14, 2020
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Feb 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the efficacy of ceftolozane/tazobactam (MK-7625A) plus metronidazole versus meropenem in adults diagnosed with complicated intra-abdominal infection (cIAI). The primary hypothesis is ceftolozane/tazobactam plus metronidazole is non-inferior to meropenem, as measured by the clinical response rate at the Test-of Cure (TOC) visit in the Clinically Evaluable (CE) population.
Conditions
- Complicated Intra-abdominal Infections
Interventions
Ceftolozane/TazobactamDrug
Ceftolozane 1000 mg / tazobactam 500 mg by IV infusion every 8 hours for 4 to 14 days. Participants with CrCL of 30 to ≤ 50 mL/min will receive ceftolozane 500 mg / tazobactam 250 mg.
MetronidazoleDrug
Metronidazole 500 mg by IV infusion every 8 hours for 4 to 14 days.
MeropenemDrug
Meropenem 1000 mg by IV infusion every 8 hours for 4 to 14 days. Participants with CrCL of 30 to ≤ 50 mL/min will receive IV infusion every 12 hours.
PlaceboDrug
Saline by IV infusion every 8 hours for 4 to 14 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Clinical Response (Clinical Cure or Clinical Failure) at Test of Cure (TOC) Visit: Clinically Evaluable (CE) PopulationTime frame: Up to approximately Day 30
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
Southern Medical University Nanfang Hospital ( Site 0055)
Guangzhou, China
Anhui Provincial Hospital ( Site 0033)
Hefei, Anhui, China
Navy General Hospital ( Site 0009)
Beijing, Beijing Municipality, China
Peking University Third Hospital ( Site 0002)
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Guangzhou Medical University ( Site 0026)
Guangzhou, Guangdong, China
Hainan General Hospital ( Site 0042)
Haikou, Hainan, China
Baotou Central Hospital ( Site 0013)
Baotou, Inner Mongolia, China
The First People's Hospital of Changzhou ( Site 0054)
Changzhou, Jiangsu, China
Wuxi No.2 People's Hospital ( Site 0050)
Wuxi, Jiangsu, China
Wuxi People's Hospital ( Site 0020)
Wuxi, Jiangsu, China
Subei People's Hospital ( Site 0046)
Yangzhou, Jiangsu, China
Affiliated Hospital of Jiangsu University ( Site 0049)
Zhenjiang, Jiangsu, China
The First Affiliated Hospital of Nanchang University ( Site 0029)
Nanchang, Jiangxi, China
The Second Affiliated Hospital of Nanchang University ( Site 0053)
Nanchang, Jiangxi, China
The Second Hospital of Jilin University ( Site 0048)
Changchun, Jilin, China
Liaocheng People s hospital ( Site 0014)
Liaocheng, Shandong, China
Zhongshan Hospital of Fudan University ( Site 0001)
Shanghai, Shanghai Municipality, China
Shanghai General Hospital ( Site 0016)
Shanghai, Shanghai Municipality, China
Central Hospital of Minhang District ( Site 0052)
Shanghai, Shanghai Municipality, China
Tianjin People's Hospital ( Site 0040)
Tianjin, Tianjin Municipality, China
The First Affiliated Hospital of Xinjiang Medical University ( Site 0034)
Ürümqi, Xinjiang, China
The First Hospital of Kunming ( Site 0041)
Kunming, Yunnan, China
Taizhou Hospital of Zhejiang Province ( Site 0035)
Taizhou, Zhejiang, China
The 2nd Affiliated Hospital of Wenzhou Medical University ( Site 0051)
Wenzhou, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University ( Site 0015)
Wenzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.